Oncology & Cancer
Venetoclax safe, shows promise in patients with acute myelogenous leukemia
Patients whose acute myelogenous leukemia (AML) had relapsed or was resistant to chemotherapy and those who were deemed unable to tolerate chemotherapy experienced responses to the selective BCL-2 inhibitor venetoclax (Venclexta), ...
Aug 15, 2016
0
4